D61.810
Antineoplastic chemotherapy induced pancytopenia
HCC risk adjustment mapping
CMS-HCC ESRD V24
Disorders of Immunity
Coding notes
Excludes 1 never coded together · Excludes 2 may co-exist
aplastic anemia due to antineoplastic chemotherapy (D61.1)
pancytopenia (due to) (with) aplastic anemia (D61.9) pancytopenia (due to) (with) bone marrow infiltration (D61.82) pancytopenia (due to) (with) congenital (pure) red cell aplasia (D61.01) pancytopenia (due to) (with) hairy cell leukemia (C91.4-) pancytopenia (due to) (with) human immunodeficiency virus disease (B20.-) pancytopenia (due to) (with) leukoerythroblastic anemia (D61.82) pancytopenia (due to) (with) myeloproliferative disease (D47.1)
pancytopenia (due to) (with) myelodysplastic syndromes (D46.-)
neutropenia (D70.-)
autoimmune disease (systemic) NOS (M35.9) certain conditions originating in the perinatal period (P00-P96) complications of pregnancy, childbirth and the puerperium (O00-O9A) congenital malformations, deformations and chromosomal abnormalities (Q00-Q99) endocrine, nutritional and metabolic diseases (E00-E88) human immunodeficiency virus [HIV] disease (B20) injury, poisoning and certain other consequences of external causes (S00-T88) neoplasms (C00-D49) symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified (R00-R94)
Official Guidelines for D61.810
FY 2026 ›Find D61.810 in the alphabetic index
1 index path leads to this code